56 related articles for article (PubMed ID: 38725635)
1. Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis.
Zhang X; Wu M; Chen J; Zheng K; Du H; Li B; Gu Y; Jiang J
Heliyon; 2024 May; 10(10):e30809. PubMed ID: 38774326
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials.
Xu R; Wong CHL; Chan KSK; Chiang CL
Front Oncol; 2024; 14():1386381. PubMed ID: 38887234
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38597713
[No Abstract] [Full Text] [Related]
4. Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
Yu J; Meng F; Sui W; Yu J; Shen J
Front Pharmacol; 2024; 15():1378577. PubMed ID: 38895628
[TBL] [Abstract][Full Text] [Related]
5. First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials.
Chen W; Liu H; Li Y; Xue W; Fan S; Sun J; Liu S; Liu Y; Zhang L
Front Oncol; 2024; 14():1365255. PubMed ID: 38725635
[TBL] [Abstract][Full Text] [Related]
6. Network approach in liquidomics landscape.
Santini D; Botticelli A; Galvano A; Iuliani M; Incorvaia L; Gristina V; Taffon C; Foderaro S; Paccagnella E; Simonetti S; Fazio F; Scagnoli S; Pomati G; Pantano F; Perrone G; De Falco E; Russo A; Spinelli GP
J Exp Clin Cancer Res; 2023 Aug; 42(1):193. PubMed ID: 37542343
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
Chen X; Feng L; Huang Y; Wu Y; Xie N
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612100
[TBL] [Abstract][Full Text] [Related]
8. A Gentle Introduction to Bayesian Network Meta-Analysis Using an Automated R Package.
Liu Y; Béliveau A; Wei Y; Chen MY; Record-Lemon R; Kuo PL; Pritchard E; Tang X; Chen G
Multivariate Behav Res; 2023; 58(4):706-722. PubMed ID: 36254763
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
11. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; D'Amico TA; DeCamp M; Dilling TJ; Dowell J; Gettinger S; Grotz TE; Gubens MA; Hegde A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Ng T; Otterson GA; Pacheco JM; Patel SP; Riely GJ; Riess J; Schild SE; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory K; Hughes M
J Natl Compr Canc Netw; 2022 May; 20(5):497-530. PubMed ID: 35545176
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression.
Kim JH; Jeong SY; Lee JJ; Park ST; Kim HS
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329818
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C;
J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163
[TBL] [Abstract][Full Text] [Related]
14. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy.
Ippolito MR; Martis V; Martin S; Tijhuis AE; Hong C; Wardenaar R; Dumont M; Zerbib J; Spierings DCJ; Fachinetti D; Ben-David U; Foijer F; Santaguida S
Dev Cell; 2021 Sep; 56(17):2440-2454.e6. PubMed ID: 34352223
[TBL] [Abstract][Full Text] [Related]
15. A Network Meta-Analysis of Cancer Immunotherapies
Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
Front Oncol; 2021; 11():676732. PubMed ID: 34307144
[TBL] [Abstract][Full Text] [Related]
16. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis.
Wang DD; Shaver LG; Shi FY; Wei JJ; Qin TZ; Wang SZ; Kong YJ
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2866-2884. PubMed ID: 33877652
[TBL] [Abstract][Full Text] [Related]
18. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Majem M; Cobo M; Isla D; Marquez-Medina D; Rodriguez-Abreu D; Casal-Rubio J; Bueno TM; Bernabé-Caro R; Parente DP; Ruiz-Gracia P; Arroyo MM; Paz-Ares L
J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33810441
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
